enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
enGene Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
enGene Therapeutics's operating cash flow for the twelve months ending Jul 31, 2026 was -$103.31M. For fiscal 2025 it was -$99.24M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$99.24M | – |
| FY2024 | Oct 31, 2024 | -$48.28M | – |
| FY2023 | Oct 31, 2023 | -$24.74M | – |
| FY2022 | Oct 31, 2022 | -$17.59M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$18.95M | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$30.50M | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$28.90M | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$24.96M | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$25.63M | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$22.95M | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$25.70M | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$19.57M | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$7.18M | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$14.16M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$7.37M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$6.78M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$7.30M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$4.44M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$6.22M | – |
See a number that looks wrong?